Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations.

Generate Biomedicines 已在纳斯达克申请首次公开募股 (IPO)，希望为其人工智能驱动的药物发现业务筹集超过 1 亿美元的资金。

Incubated by Flagship Pioneering, Generate applies AI to teasing out the three-dimensional structure of human proteins, including how they are folded, to determine function and design drugs that can change their activity.

Generate由Flagship Pioneering孵化，利用人工智能解析人类蛋白质的三维结构，包括它们的折叠方式，以确定其功能并设计能够改变其活性的药物。

In December, it started two phase 3 trials of its lead AI-designed drug candidate, long-acting anti-TSLP antibody GB-0895, in patients with severe asthma whose symptoms are inadequately controlled using current therapies. AI was used in the design of the antibody to achieve ultra-high-affinity TSLP binding, extended half-life, and high specificity for its target, reducing the risk of side effects..

去年12月，该公司启动了其主要由人工智能设计的药物候选物——长效抗TSLP抗体GB-0895——在症状未通过现有疗法得到充分控制的重症哮喘患者中的两项III期试验。该抗体的设计利用了人工智能技术，以实现超高亲和力的TSLP结合、延长半衰期，并提高对目标靶点的高特异性，从而降低副作用风险。

The

The

SOLAIRIA

索拉里亚

‑

‑

1

1

and

和

SOLAIRIA

索拉里亚

‑

‑

2

2

studies have a target enrolment of 1,600 adult and adolescent patients and will see how GB-0895 compares to placebo in reducing clinically significant asthma exacerbations over 52 weeks when added to current therapies.

研究目标是招募1600名成年和青少年患者，将观察GB-0895在加入现有疗法后，与安慰剂相比，在52周内减少临床上显著的哮喘急性发作的效果。

The drug is being administered just twice a year in the two studies, which could differentiate it from other biologic therapies for severe uncontrolled asthma, such as Amgen's TSLP-directed Tezspire (tezepelumab), Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab), and IL-5 blockers like GSK's Nucala (mepolizumab), which are dosed once a month..

在这两项研究中，该药物每年仅给药两次，这可能使其区别于其他用于治疗严重不受控制哮喘的生物疗法，如安进公司针对TSLP的Tezspire（tezepelumab）、赛诺菲/再生元公司的IL-4和IL-13抑制剂Dupixent（dupilumab），以及葛兰素史克的IL-5阻断剂Nucala（mepolizumab），这些药物每月给药一次。

If it makes it through to market, GB-0895 could provide an alternative to GSK's recently approved, twice-yearly IL-5 inhibitor

如果能够成功进入市场，GB-0895 可能会提供一种替代 GSK 最近获批的半年一次的 IL-5 抑制剂的选择。

Exdensur

扩展传感器

(depemokimab), which is approved specifically for severe asthma with type 2 inflammation.

（depemokimab），该药物特别适用于伴有2型炎症的重度哮喘。

Generate's pipeline also includes two other clinical trial-ready candidates for oncology indications, namely MMAE-directed antibody GB-4362 – intended to reduce toxicity with MMAE-carrying antibody-drug conjugates – and GB-5267, a cell therapy that targets MUC16 and is being developed for ovarian cancer..

Generate的管线还包括另外两个针对肿瘤适应症的临床试验准备就绪的候选药物，分别是MMAE导向抗体GB-4362——旨在降低携带MMAE的抗体药物偶联物的毒性——以及靶向MUC16并正在开发用于卵巢癌的细胞疗法GB-5267。

According to the prospectus for the IPO, the proceeds will go towards its phase 3 programme, starting a phase 1b trial of GB-0895 in chronic obstructive pulmonary disease (COPD), and taking its cancer candidates through phase 1 testing.

根据首次公开募股的招股说明书，所得款项将用于其第三阶段计划，启动GB-0895在慢性阻塞性肺病（COPD）中的第一阶段1b试验，并将其癌症候选药物推进到第一阶段测试。

Generate has proved very successful in raising venture capital, closing a $273 million third-round in 2023 and a $370 million second round two years earlier. It has also forged two R&D alliances, with Novartis and Amgen, worth up to $1 billion-plus and $1.9 billion, respectively. Pricing plans for the IPO have not yet been disclosed..

Generate 在筹集风险资本方面取得了巨大成功，2023年完成了2.73亿美元的第三轮融资，两年前完成了3.7亿美元的第二轮融资。该公司还与诺华和安进达成了两项研发联盟，分别价值超过10亿美元和19亿美元。IPO的定价计划尚未披露。

The filing with the US Securities & Exchange Commission (SEC) comes shortly after two other biotech IPOs, for

向美国证券交易委员会（SEC）提交的文件紧随另外两起生物技术公司IPO之后，

Eikon Therapeutics and Veradermics

义康治疗学与维拉德米克斯

, closed this week, overshooting their original fundraising targets by a comfortable margin.

，本周关闭，以相当大的幅度超过了他们最初的筹款目标。

Two other companies –

两家其他公司——

AgomAb Therapeutics and Spyglass Pharma

阿戈马布治疗公司和望远镜制药公司

– are also on course to complete listings this week, already setting up 2026 as a potentially bumper year for biotech IPOs.

——也将在本周完成上市，2026年已经有望成为生物技术公司IPO的丰收年。

Generate is seeking to list on the Nasdaq under the GEMB symbol.

Generate计划在纳斯达克上市，股票代码为GEMB。